ArticleGastroenterology & hepatology2025
Pan-Gut Dysmotility in Parkinson Disease.
Article in Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson disease (PD) is a rapidly growing neurologic disorder affecting millions of people worldwide. While bradykinesia, rigidity, and tremor define its motor phenotype, gastrointestinal (GI) symptoms are highly prevalent and significantly impact quality of life. These symptoms often persist or worsen despite dopaminergic therapy and result from dysmotility involving the entire GI tract. Notably, many patients exhibit substantial objective motility disturbances despite minimal or no reported symptoms. This mismatch reflects impaired gut-brain communication and profound gut hyposensitivity, which dampen symptom perception and awareness. As such, reliance solely on patient-reported symptoms risks overlooking clinically significant dysmotility that can impair drug absorption, promote malnutrition, and increase the risk of complications such as bacterial overgrowth or aspiration. In response, diagnostic strategies are evolving to incorporate objective assessments, including videofluoroscopy, cough reflex testing, high-resolution manometry, and transit studies. These tools enhance the detection and characterization of unrecognized GI dysfunction in PD. A more nuanced, mechanism-based approach to evaluation is critical, as improved recognition of pan-gut dysmotility can guide individualized management strategies. This article reviews the underlying mechanisms of GI dysfunction in PD and provides a framework for its clinical assessment and care, emphasizing the need for proactive, objective evaluation beyond symptom reporting alone.
Indexed as
Identifiers
41624804PMC12853701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.